Skip to content
Exclusive CEO Interviews
Press Releases profile photo

Press Releases

Would you like us to consider a press release for publication? Please email david@onyxnewsroom.com.

ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma

ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma

✨ Onyx Summary ImmunityBio reported updated data from its ongoing QUILT-106 study showing durable complete responses of up to 15 months with an off-the-shelf CD19 CAR-NK cell therapy combined with rituximab in patients with Waldenström lymphoma, with 100% disease control observed to date. The chemotherapy-free, lymphodepletion-free outpatient regimen highlights the potential

ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% Increase Year-Over-Year

ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% Increase Year-Over-Year

✨ Onyx Summary ImmunityBio, Inc. reported preliminary fourth-quarter 2025 net product revenue of approximately $38.3 million, up 20% sequentially and more than fourfold year over year, reflecting accelerating adoption of ANKTIVA and continued commercial momentum. The update also highlighted expanding global regulatory approvals for ANKTIVA and a strengthened cash position

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

MALVERN, Pa., Jan. 15, 2026 – Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced positive preliminary 12-month data (~50% of patients evaluated to date) from the Phase 2 ArMaDa clinical trial evaluating OCU410 (AAV5-RORA), its novel modifier gene therapy

Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)

Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)

✨ Onyx Summary Sun Pharmaceutical Industries Limited announced that UNLOXCYT™ (cosibelimab-ipdl) is now commercially available in the U.S. for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation. The launch follows an FDA label update reflecting long-term clinical trial data

Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ

Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ

✨ Onyx Summary ImmunityBio, Inc. announced that Saudi Arabia’s Saudi Food and Drug Authority has approved ANKTIVA plus BCG for adult patients with BCG-unresponsive non-muscle invasive bladder cancer, expanding the therapy’s regulatory footprint beyond the U.S., U.K., and EU. The approval supports ImmunityBio’s international commercial strategy,

ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination with Checkpoint Inhibitors in Non-Small Cell Lung Cancer

ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination with Checkpoint Inhibitors in Non-Small Cell Lung Cancer

✨ Onyx Summary ImmunityBio, Inc. reported positive clinical results for its investigational immunotherapy ANKTIVA in non-small cell lung cancer, demonstrating statistically significant immune restoration and an association between lymphocyte recovery and improved survival in checkpoint-experienced patients. Data from the QUILT-2.023 and QUILT-3.055 studies support a potential shift beyond chemotherapy

NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security

NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security

✨ Onyx Summary NantWorks, LLC and ImmunityBio, Inc. announced the inaugural U.S.–Saudi Biotech Alliance Summit, to be held alongside the J.P. Morgan Healthcare Conference on January 14, 2026, bringing together U.S. and Saudi leaders across biotechnology, healthcare, manufacturing, AI, and finance. The invitation-only summit is structured to

Cellares Expands Global Smart Factory Network With European Headquarters in the Netherlands

Cellares Expands Global Smart Factory Network With European Headquarters in the Netherlands

✨ Onyx Summary Cellares has secured a long-term lease for a new European IDMO Smart Factory at Leiden Bio Science Park, establishing its European headquarters and adding regional automated manufacturing capacity. The move strengthens Cellares’ global network to support time-sensitive, patient-specific cell therapy programs with standardized, scalable production as partners advance

Vibrant Therapeutics Raises $61M and Appoints Han Lee, Ph.D. as Co-CEO

Vibrant Therapeutics Raises $61M and Appoints Han Lee, Ph.D. as Co-CEO

✨ Onyx Summary Vibrant Therapeutics raised $61 million in new financing, bringing total capital to $100 million, appointed Han Lee, Ph.D., as co-CEO, and secured FDA acceptance of the IND for its lead EGFR-targeted program VIB305. The funding and regulatory milestone position the company to expand globally, advance U.S.

Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference

Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference

✨ Onyx Summary Legend Biotech Corporation highlighted strong commercial momentum for CARVYKTI®, surpassing 10,000 patients treated globally, expanding manufacturing capacity, and securing label updates supporting overall survival benefits, while outlining plans to drive profitability in 2026. The update also underscored pipeline expansion across frontline, allogeneic, and in vivo CAR-T programs,

Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference

Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference

✨ Onyx Summary Perspective Therapeutics, Inc. outlined 2026 strategic priorities focused on advancing its targeted radiopharmaceutical pipeline, highlighted by continued dose optimization and maturing clinical data for VMT-α-NET, alongside progress in melanoma and solid tumor programs. The company also emphasized ongoing expansion of manufacturing infrastructure and anticipated clinical updates throughout 2026

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference

EMERYVILLE, Calif., Jan. 12, 2026 – Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, provided today a corporate update and outlined its strategic priorities for 2026. “Our strong execution in 2025 solidifies our leadership position in autoimmune CAR T

Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference

Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference

✨ Onyx Summary Lexicon Pharmaceuticals, Inc. outlined multiple 2026–2027 catalysts at the J.P. Morgan Healthcare Conference, including progress in Phase 3 sotagliflozin programs for hypertrophic cardiomyopathy and type 1 diabetes, advancement of pilavapadin for neuropathic pain, and milestone-driven partnerships with Viatris and Novo Nordisk. The update highlighted a strengthened